Mannose 6-phosphate-modified bovine serum albumin nanoparticles for controlled and targeted delivery of sodium ferulate for treatment of hepatic fibrosis

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 9, 2009, Pages 1155-1161

  Li, Feng Qian ^a   Su, Hua ^b   Chen, Xu ^a   Qin, Xian Ju ^a   Liu, Ji Yong ^b   Zhu, Quan Gang ^b   Hu, Jin Hong ^b  

^a SHANGHAI EIGHTH PEOPLE'S HOSPITAL   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Desolvation procedure; Hepatic stellate cells specificity; Liver targeting; Neoglycoprotein nanoparticles; Sodium ferulate

Indexed keywords

BOVINE SERUM ALBUMIN; DRUG CARRIER; FERULIC ACID; MANNOSE 6 PHOSPHATE; NANOPARTICLE; NEOGLYCOPROTEIN; COUMARIC ACID; GLYCOPROTEIN; MANNOSE PHOSPHATE; MANNOSE-6-PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG RELEASE; DRUG TARGETING; DRUG TISSUE LEVEL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER CELL; LIVER FIBROSIS; MALE; MORPHOLOGY; MOUSE; NANOENCAPSULATION; NONHUMAN; PROTEIN MODIFICATION; RAT; SOLVATION; STELLATE CELL; SYNTHESIS; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; HISTOLOGY; LIVER; LIVER CIRRHOSIS; METHODOLOGY; TISSUE DISTRIBUTION;

ANIMALS; COUMARIC ACIDS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLYCOPROTEINS; LIVER; LIVER CIRRHOSIS; MALE; MANNOSEPHOSPHATES; MICE; NANOPARTICLES; RATS; SERUM ALBUMIN, BOVINE; TISSUE DISTRIBUTION;

EID: 85047682865     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.09.0004     Document Type: Article

References (25)

1. Alcolado R et al. Pathogenesis of liver fibrosis. Clin Sci 1997; 92: 103-112.
2. Hautekeete ML, Geerts A. The hepatic stellate (ito) cell: its role in human liver disease. Virchows Arch 1997; 430: 195-207.
3. Gressner AM. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292: 447-452.
4. Wu J, Danielsson A. Inhibition of hepatic fibrogenesis: a review of pharmacologic candidates. Scand J Gastroenterol 1994; 29: 385-391.
5. Schuppan D et al. Hepatic fibrosis - therapeutic strategies. Digestion 1998; 59: 385-390.
6. 4 intoxication in the rat. Hepatology 1996; 23: 1530-1537.
7. Beljaars L et al. Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology 1999; 29: 1486-1493.
8. 28-HSA). Liver 2001; 21: 320-328.
9. Barone E et al. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology 2009; 10: 97-108.
10. Wang H et al. Antagonizing effect of sodium ferulate on the changes of hepatic antioxidative function induced by ethanol in mice. Acta Pharm Sin 1997; 32: 511-514.
11. Huang J et al. Mechanisms of sodium ferulate inhibition of collagen synthesis in hepatic stellate cells. Acta Pharm Sin 2004; 39: 577-580.
12. Li FQ et al. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int J Pharm 2008; 349: 274-282.
13. Zhang J et al. Synthesis of a targeting drug for antifibrosis of liver; a conjugate for delivering glycyrrhetin to hepatic stellate cells. Glycoconjugate J 2002; 19: 423-429.
14. Dubois M et al. Colorimetric method for determination of sugars and related substances. Anal Chem 1956; 28: 350-356.
15. Smith PK et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
16. Langer K et al. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003; 257: 169-180.
17. Wartlick H et al. Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles. J Control Release 2004; 96: 483-495.
18. Li FQ et al. Development of a gradient reversed-phase HPLC method for the determination of sodium ferulate in beagle dog plasma. J Chromatogr B 2007; 846: 319-322.
19. Kountouras J et al. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-311.
20. Harms G et al. Glycosyl receptors in macrophage subpopulations of rat spleen and lymph node. A comparative study using neoglycoproteins and monoclonal antibodies ED1, ED2 and ED3. Cell Tissue Res 1990; 262: 35-40.
21. Harms G et al. Double immunohistochemical demonstration of antigen expressing and DNA-incorporated 5-bromodeoxyuridine in frozen and plastic embedded sections. Acta Histochem 1988; 36S: 353-359.
22. Lochmann D et al. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm 2005; 59: 419-429.
23. Roser M et al. Surface-modified biodegradable albumin nanoand microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998; 46: 255-263.
24. Lin W et al. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release 2001; 71: 117-126.
25. Bilati U et al. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm 2005; 59: 375-388.